

# Investigations in GABA<sub>A</sub> receptor antibody-associated encephalitis



Marianna Spatola, MD  
 Mar Petit-Pedrol, BS  
 Mateus Mistieri  
 Simabukuro, MD  
 Thaís Armangué, MD,  
 PhD  
 Fernanda J. Castro, MD  
 Maria I. Barcelo Artigues,  
 MD  
 Maria R. Julià Benique,  
 MD  
 Leslie Benson, MD  
 Mark Gorman, MD  
 Ana Felipe, MD  
 Ruben L. Caparó Oblitas,  
 MD  
 Myrna R. Rosenfeld, MD,  
 PhD  
 Francesc Graus, MD,  
 PhD  
 Josep Dalmau, MD, PhD

Correspondence to  
 Dr. Dalmau:  
[jdalmau@clinic.ub.es](mailto:jdalmau@clinic.ub.es)

## ABSTRACT

**Objective:** To report the clinical features, comorbidities, receptor subunit targets, and outcome in patients with anti-GABA<sub>A</sub> receptor (GABA<sub>A</sub>R) encephalitis.

**Methods:** Clinical study of 26 patients, including 17 new (April 2013–January 2016) and 9 previously reported patients. Antibodies to  $\alpha$ 1,  $\beta$ 3, and  $\gamma$ 2 subunits of the GABA<sub>A</sub>R were determined using reported techniques.

**Results:** Patients' median age was 40.5 years (interquartile range 48.5 [13.75–62.35] years; the youngest 2.5 months old; 13 female). Symptoms included seizures (88%), alteration of cognition (67%), behavior (46%), consciousness (42%), or abnormal movements (35%). Comorbidities were identified in 11 (42%) patients, including 7 tumors (mostly thymomas), 2 herpesvirus encephalitis (herpes simplex virus 1, human herpesvirus 6; coexisting with NMDAR antibodies), and 2 myasthenia without thymoma. Brain MRI was abnormal in 23 (88%) patients, showing in 20 (77%) multifocal, asynchronous, cortical-subcortical T2/fluid-attenuated inversion recovery abnormalities predominantly involving temporal (95%) and frontal (65%) lobes, but also basal ganglia and other regions. Immunologic or tumor therapy resulted in substantial improvement in 18/21 (86%) assessable patients; the other 3 (14%) died (2 status epilepticus, 1 sepsis). Compared with adults, children were more likely to have generalized seizures ( $p = 0.007$ ) and movement disorders ( $p = 0.01$ ) and less likely to have a tumor ( $p = 0.01$ ). The main epitope targets were in the  $\alpha$ 1/ $\beta$ 3 subunits of the GABA<sub>A</sub>R.

**Conclusions:** Anti-GABA<sub>A</sub>R encephalitis is characterized by frequent seizures and distinctive multifocal cortical-subcortical MRI abnormalities that provide an important clue to the diagnosis. The frequency of symptoms and comorbidities differ between children (more viral-related) and adults (more tumor-related). The disorder is severe but most patients respond to treatment.

**Neurology**® 2017;88:1012–1020

## GLOSSARY

**CBA** = cell-based assay; **FLAIR** = fluid-attenuated inversion recovery; **GABA<sub>A</sub>R** = GABA<sub>A</sub> receptor; **HHV6** = human herpesvirus 6; **HSV1** = herpes simplex 1; **PSCT** = peripheral stem cell transplantation.

The GABA<sub>A</sub> receptor (GABA<sub>A</sub>R) is a ligand-gated chloride channel that mediates fast inhibitory synaptic transmission in the CNS. At the synapse, most GABA<sub>A</sub>Rs contain 2  $\alpha$  subunits, 2  $\beta$  subunits, and 1  $\gamma$  subunit, arranged as  $\gamma$ - $\beta$ - $\alpha$ - $\beta$ - $\alpha$ . Pharmacologic or genetic alteration of this receptor causes seizures,<sup>1–7</sup> and we recently reported that human autoantibodies to the  $\alpha$ 1 and  $\beta$ 3 subunits associate with seizures and status epilepticus in the context of autoimmune encephalitis.<sup>8</sup> Since then, the  $\gamma$ 2 subunit was also found to be a target of autoantibodies in one patient,<sup>9</sup> and subsequently confirmed in other cases.<sup>10</sup> Recognition of anti-GABA<sub>A</sub>R encephalitis is important because the seizures may be refractory to antiepileptic drugs unless the autoimmune response is treated. It is unclear whether the clinical features associated with antibodies against


Editorial, page 1010

Supplemental data  
 at [Neurology.org](http://Neurology.org)

From the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) (M.S., M.P.-P., T.A., M.R.R., F.G., J.D.), University of Barcelona, Spain; University of Lausanne (UNIL) (M.S.), Switzerland; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (M.P.-P., T.A., M.R.R., J.D., F.G.), Madrid, Spain; Neurology Service (T.A., J.D.), Hospital Sant Joan de Déu, Barcelona, Spain; Neurology Division, Hospital das Clínicas (M.M.S.), São Paulo University, Brazil; Hospital de Base (F.J.C.), Brasília, Brazil; Service of Neurology (M.I.B.A.) and Service of Immunology (M.R.J.B.), University Hospital of Son Espases, Mallorca, Spain; Department of Neurology (L.B., M.G.), Children's Hospital, Boston, MA; Pediatric Neurology Section (A.F.), Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Nacional Edgardo Rebagliati Martins (R.L.C.O.), Lima, Peru; Department of Neurology (M.R.R., J.D.), University of Pennsylvania, Philadelphia; Service of Neurology (F.G., J.D.), Hospital Clínic; and Catalan Institution for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain.

Go to [Neurology.org](http://Neurology.org) for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

**Figure 1** Reactivity of patient's antibodies with the GABA<sub>A</sub> receptor (GABA<sub>A</sub>R)



Rat brain immunostaining with CSF of a patient with antibodies against the  $\alpha 1$ ,  $\beta 3$ , and  $\gamma 2$  subunits of the GABA<sub>A</sub>R (A), compared with that of another CSF sample containing antibodies against  $\alpha 1$  and  $\beta 3$  subunits (C). Note the remarkable similarity of immunostaining of the samples of both patients. (B, D) Reactivity of the same patients' CSF samples with the corresponding HEK cells expressing the  $\alpha 1\beta 3\gamma 2$  subunits (B), and HEK cells expressing the  $\alpha 1\beta 3$  subunits (D). For patients with antibodies against  $\alpha 1\beta 3$  subunits, adding the  $\gamma 2$  subunit did not increase the intensity of reactivity with  $\alpha 1\beta 3$  (data not shown). The CSF of a patient without these antibodies serves as control (E, F). Scale bar rat brain = 2 mm, scale bar HEK cells = 10  $\mu$ m.

the  $\gamma 2$  subunit are different from those associated with antibodies against the  $\alpha 1$  and  $\beta 3$  subunits. Moreover, since anti-GABA<sub>A</sub>R encephalitis was described recently, the spectrum of symptoms has not been fully defined. We describe the clinical, MRI, and immunologic features of 17 newly identified patients and 9 previously reported but not investigated for antibodies against the  $\gamma 2$  subunit of the receptor.

**METHODS Patients, controls, clinical definitions, and sample collection.** Between April 2013 and January 2016, we investigated the sera or CSF of 2,914 patients with suspected autoimmune neurologic disorders. We included in the current study only those patients who fulfilled the following 3 criteria (figure e-1 at Neurology.org): (1) syndrome compatible with possible autoimmune encephalitis,<sup>11</sup> (2) serum or CSF reactivity with neuropil of rat brain suggesting a cell surface or synaptic target antigen, and (3) reactivity in a specific GABA<sub>A</sub>R cell-based assay (CBA) using live HEK cells expressing  $\alpha 1\beta 3$  or  $\alpha 1\beta 3\gamma 2$  subunits. In addition, we included 9 patients (1–6, 9, 11, and 12 from our original report describing the GABA<sub>A</sub>R antibodies) whose serum or CSF fulfilled the above criteria; the other 9 patients from that study were excluded because the antibodies did not show brain reactivity.<sup>8</sup>

Clinical information was obtained from questionnaires completed by physicians. The severity of symptoms was evaluated by

the modified Rankin Scale.<sup>12</sup> The outcome at the last follow-up was defined as complete recovery (able to return to all previous activities), partial recovery (objective improvement but unable to return to all activities), no improvement, or death. Controls (total 461) for tissue immunohistochemistry and CBA antibody studies included serum or CSF of 169 patients with autoimmune encephalitis (paraneoplastic or nonparaneoplastic), 114 with opsoclonus-myoclonus, 117 with stiff-person syndrome, 20 with neurodegenerative disorders, and 41 healthy blood donors.

**Immunohistochemical studies.** All samples were screened for reactivity with rat brain sections using previously reported immunohistochemical methods.<sup>8,13</sup> Specific neuronal surface targets were investigated with CBA that included 13 autoantigens (NMDAR, AMPAR, GABA<sub>B</sub>R, GABA<sub>A</sub>R, LGI1, CASPR2, DPPX, GlyR, GAD65, IgLON5, mGluR5, Dopamine2R, neurexin-3 $\alpha$ ), as reported.<sup>13–18</sup> The CBA for GABA<sub>A</sub>R antibodies is described in the supplemental material.

**Standard protocol approvals, registrations, and patient consents.** All patients gave written informed consent for use of samples and clinical information. This study was approved by the Institutional Review Board of the Hospital Clinic in Barcelona, Spain.

**Statistical analysis.** Comparisons between adults and children, and between patients with and without tumor, were assessed with the 2-tailed Fisher exact test and Mann-Whitney *U* test. Results <0.05 were regarded as statistically significant.

**RESULTS** Seventeen newly identified and 9 previously reported patients fulfilled the indicated criteria

for anti-GABA<sub>A</sub>R encephalitis. These 26 patients, but none of the 461 controls, had antibodies identified with rat brain immunostaining and live HEK CBA expressing  $\alpha 1\beta 3$  subunits of the GABA<sub>A</sub>R (figures 1 and e-2). Among the 16 patients with paired serum and CSF samples, 14 had antibodies in both and 2 only in serum. The samples of all 26 patients reacted with live neurons (data not shown) similarly to those previously reported. Parallel studies in all 461 controls with live HEK cells expressing  $\alpha 1\beta 3\gamma 2$  subunits of the GABA<sub>A</sub>R (expression of individual subunits confirmed with commercial antibodies) did not reveal additional patients, indicating the absence of patients with isolated  $\gamma 2$  antibodies in our study. Indeed, all patients with  $\gamma 2$  antibodies (8/26, 31%) also had antibodies against the  $\alpha 1$  or  $\beta 3$  subunits (see supplemental material and figure e-3).

Detailed clinical features of the 17 newly identified patients are described in table 1, and of the 26 pooled cases in tables 2 and e-1. The median age of all patients was 40.5 years (interquartile range 48.5 [13.75–62.35] years), including 15 adults and 11 children; 13 were (50%) female. The median follow-up was 9 months (range 2 weeks–7 years), and the median duration of symptoms by the time of diagnosis was 2 months (range 1 week–5 years).

Tumor, viral, and other autoimmune associations occurred in 11 patients (table 1). Seven of these patients had an underlying tumor: 4 thymoma (1 with LGI1 antibodies, 1 with myasthenia), 1 small-cell lung cancer, 1 rectal cancer in association with HIV, and 1 multiple myeloma treated with autologous peripheral stem cell transplantation (PSCT) and lenalidomide (the autoimmune encephalitis developed 10 months after PSCT). Another 2 patients developed the autoimmune encephalitis a few weeks after viral encephalitis, one post herpes simplex 1 (HSV1) encephalitis and the other post human herpesvirus 6 (HHV6) encephalitis. By the time of the autoimmune encephalitis, both patients had GABA<sub>A</sub>R and NMDAR antibodies that were not present during the viral infection. Another 2 patients had myasthenia without thymoma. One of the patients with coexisting GABA<sub>A</sub>R and NMDAR antibodies is described in the supplemental material; the patient with thymoma and LGI1 antibodies has been reported previously.<sup>19</sup>

The most frequent (core) symptoms included seizures (23/26, 88%), cognitive impairment (n = 16/24, 67%, 2 babies excluded from analysis), altered behavior (12/26, 46%), decreased level of consciousness (11/26, 42%), and movement disorders (9/26, 35%). Status epilepticus occurred in 11 (48%) of the 23 patients with seizures, and 7 (64%) of them required pharmacologic coma. Seizures accompanied by at least another core symptom occurred in 23/26 (88%) patients and by at least 2 core symptoms in 14/26 (54%). Nine

(35%) patients developed abnormal movements, including 7/11 (64%) children who showed orofacial dyskinesias, dystonic postures, or generalized choreoathetosis, and 2/15 (13%) adults, both showing facial twitches and cramps. Two of the 11 children developed the symptoms as part of a postviral encephalitis (coexisting with NMDAR antibodies) and 1 after vaccination for yellow fever (without NMDAR antibodies). The latter was a 10-month-old baby girl (patient 8, video) who developed a clinical picture that initially suggested anti-NMDAR encephalitis, including dysautonomia and orofacial and limb dyskinesias without NMDAR antibodies in serum and CSF.

CSF was abnormal in 15 of 26 (58%) patients including pleocytosis (6–154 leukocytes/mm<sup>3</sup>), increased protein concentration (0.52–0.85 g/L), or oligoclonal bands (table 2). EEG was available for 21 patients: 16 (76%) had epileptiform activity, mostly unilateral or bilateral periodic epileptiform discharges involving the temporal lobes (9 associated with focal or diffuse slow activity) and 5 (24%) had slow activity. Brain biopsy, performed in patient 15, demonstrated mild parenchymal and perivascular lymphocytic infiltrates without vessel wall involvement, and microglial activation (data not shown).

T2/fluid-attenuated inversion recovery (FLAIR) brain MRI abnormalities were identified in 23/26 (88%) patients. In 20 (77%), the abnormalities were multifocal, involving both gray and white matter in 2 or more of the following regions: temporal (95%, 16 bilateral, 3 unilateral), frontal (65%, 10 bilateral, 3 unilateral), parietal (25%, 3 bilateral, 2 unilateral), occipital (15%, 2 bilateral, 1 unilateral), basal ganglia (15%), cerebellum (10%), or brainstem (5%). Only 2 patients had isolated unilateral involvement of the temporal lobe, another patient had isolated unilateral parietal involvement, and 3 had normal MRI. The multifocal abnormalities involved cortical and subcortical regions (figure 2), without diffusion restriction (except for patient 7) and without gadolinium enhancement (except for patient 14, who had focal gyriform leptomeningeal enhancement, and 16, who had mild hippocampal enhancement). The multifocal T2/FLAIR changes were asynchronous, with some appearing while others were disappearing during the course of the disease. In one of the patients (case 17), the MRI abnormalities persisted during short periods (4–6 weeks) in which the patient was remarkably free of seizures or other symptoms.

Treatment information was available for 23 patients: 13 (56%) received first-line immunotherapy (corticosteroids, plasma exchange, IV immunoglobulin), 8 (35%) first- and second-line immunotherapy (rituximab, azathioprine, cyclosporine, or cyclophosphamide), and 2 (9%) were only treated with anti-epileptics. At the last follow-up, 18 of 21 (86%)

**Table 1** Main clinical features and antibody specificity in 17 new patients with anti-GABA<sub>A</sub> receptor (GABA<sub>A</sub>R) encephalitis

Patient, sex, age, y	Prodromal features	Tumor; other autoimmune disorders	Main clinical features; mRS at the peak of disease	CSF	EEG	MRI (increased T2/FLAIR signal)	Immunotherapy and tumor treatment	Last follow-up, mo; recovery; mRS	GABA <sub>A</sub> R subunit; additional Ab
1, F, 58	Fatigue, fever	Thymoma (identified at diagnosis)	Memory loss; 2	Normal	Intermittent slowing	Bilateral insula and basal ganglia	Steroids, thymectomy	9; partial; mRS 1	S: 1/640; CSF: 1/20; α1, β3
2, F, 88	None	Thymoma (identified at diagnosis)	dLOC, cognitive decline, L hemiplegia; 5	Normal	NA	R temporal, bilateral frontal lobes	PE, thymectomy	10; partial; mRS 3	S: NA; CSF: 1/20; α1
3, F, 74	Headache	None	Personality change, apathy, anxiety, memory loss, speech disorder, dLOC, focal seizures, SE; 5	Normal	Bilateral temporal PED	L temporal lobe, mild hippocampal Gd+	Steroids, AZA	2; partial; mRS 2; died 6 months later of sepsis	S: NA; CSF: 1/20; α1, β3
4, M, 60	None	None	Focal auditory seizures; R facial twitches, R hemibody paresthesia, dysarthria and aphasia; 5	Normal	NA	L temporal and bilateral frontal lobes	Steroids	12; partial; mRS 2	S: 1/160; CSF: 1/40; α1, β3, γ2
5, F, 66	Skin rash, vomiting	Thymoma (preceded encephalitis)	Right arm paresthesia; 1	Normal	NA	Bilateral frontal, temporal, parietal lobes	Steroids, thymectomy	3; partial; mRS 1	S: 1/40; CSF: 1/20; α1, γ2
6, M, 36	HIV	Rectal cancer (preceded encephalitis)	Seizures, confusion, dLOC; 2 months later hearing difficulty, slurred speech; 4	Normal	Intermittent diffuse slowing	L operculum and bilateral temporal lobes	Steroids, cancer treatment	12; partial; mRS 2	S: 1/160; CSF: 1/20; β3, γ2
7, M, 62	None	10 months posttransplant for multiple myeloma	Seizures, cognitive deterioration, altered mental status, dLOC, coma; 5	Normal	Diffuse slowing	Frontal, temporal, and occipital lobes with diffusion restriction	Steroids, PE	2; complete; mRS 0	S: >1/1280; CSF: NA; β3
8, F, 10 mo	Yellow fever vaccine	None	Focal motor seizures, involuntary movements, dLOC, coma, SE, autonomic instability; 5	Normal	Diffuse slowing, epileptiform activity	Normal CT and MRI	Steroids, IVIg	8; partial; mRS 4	S: >1/640; CSF: 1/40; β3
9, M, 15 mo	HSV1 encephalitis	None	8 weeks after HSE: irritability, focal motor refractory seizures, SE, choreoathetosis, ataxia, dysphagia; 5	53 WBC, EP (0.83)	Generalized bilateral epileptiform activity	New increased T2/FLAIR signal in bilateral frontal and temporal lobes	Steroids, PE, RTX	14; partial; mRS 4	S: 1/80; CSF: 1/20; α1, β3, γ2; NMDAR
10, F, 45	Headache, flushing	Myasthenia gravis, metastatic thymoma	Focal motor seizures, mood and behavioral change, memory loss, dysautonomia; new pleural metastasis; 3	EP	R temporal PED and L epileptiform activity	Bilateral temporal lobes	Steroids, PE, surgical removal of metastasis	3; complete; mRS 0	S: >1/640; CSF: 1/40; α1, β3; LGI1
11, F, 14	Headache, malaise	None	Seizures, abnormal movements; NA	51 WBC	NA	Normal (1 week from disease onset)	NA	NA	S: 1/40; CSF: NA; α1, β3, γ2
12, F, 63	None	Small cell lung cancer (identified at diagnosis)	Focal motor seizures, memory loss, personality change, ataxia, gait problems; 6 months later: hallucinations, choreiform movements; 3	44 WBC, EP (0.52), OCB	Diffuse slowing, L hemisphere PED	Bilateral temporal lobes and basal ganglia	NA	NA	S: 1/40; CSF: negative; α1, β3, γ2
13, M, 53	Headache, vomiting	Myasthenia gravis; no tumor	Focal motor seizures with secondary generalization, cognitive decline; 4	52 WBC	Diffuse slowing, L PED	Bilateral temporal lobes, L frontal lobe and R occipital lobe	No immunotherapy (only AED)	1.5; partial; mRS 1	S: NA; CSF: 1/40; α1, β3
14, M, 16	Headache, weight loss, vomiting	None	Seizures, personality change, memory loss, insomnia, L dysmetria and weakness, dysautonomia; 3	10 WBC, OCB	Diffuse and focal slowing, bilateral PED	Bilateral temporal, frontal and occipital lobes, focal leptomeningeal Gd+	Steroids, IVIg, PE, RTX	3; complete; mRS 0	S: 1/320; CSF: 1/80; β3, γ2

Continued

**Table 1** Continued

Patient, sex, age, y	Prodomal features	Tumor; other autoimmune disorders	Main clinical features; the peak of disease	CSF	EEG	MRI (increased T2/FLAIR signal)	Immunotherapy and tumor treatment	Last follow-up, mo; recovery; mRS	GABA <sub>A</sub> R subunit; additional Ab
15, F, 2.5 mo	HHV-6 encephalitis	None	5 weeks after HHV6 encephalitis: seizures, hypoactivity, orofacial and generalized dyskinesias, dLOC; 5	40 WBC, EP (0.85)	Asymmetric slowing, bilateral epileptiform activity	No new abnormalities	Steroids, IVIg	6; partial (only) seizures and dyskinesias improved; mRS 4	S: 1/160; CSF: >1/320; β3, γ2; NMDAR
16, F, 57	None	Myasthenia gravis, uterine tumor (remote history)	Generalized and focal seizures, mood disorder, hallucinations, aphasia, dysphagia requiring nasogastric feeding; 4	Normal WBC and protein, OCB	Bilateral frontotemporal epileptiform activity	Bilateral frontal and temporal lobes, mild hippocampal Gd+	Steroids, PE	1.5; partial; mRS 3	S: > 1/1280; CSF: >1/320; α1, β3; NMDAR
17, M, 13	None	None	History of focal seizures successfully treated with phenytoin; 1 year later: episodes of focal motor seizures, secondary generalization, epilepsy partialis continua, psychomotor agitation; 2	Normal	Asymmetric slowing R > L, no epileptiform activity	Bilateral parietal and occipital lobes, R frontal lobe; some abnormalities persisted during periods free of symptoms	Steroids, IVIg, RTX	8; complete; mRS 0	S: > 1/1280; CSF: >1/320; α1, β3

Abbreviations: Ab = antibodies; AED = antiepileptic drugs; AZA = azathioprine; dLOC = decreased level of consciousness; EP = elevated CSF protein concentration (>0.45 g/L); FLAIR = fluid-attenuated inversion recovery; Gd+ = gadolinium enhancement; HHV6 = human herpesvirus 6; HSE = herpes simplex encephalitis; HSV1 = herpes simplex 1; IVIg = IV immunoglobulins; mRS = modified Rankin Scale; NA = not available; OCB = CSF oligoclonal bands; PE = plasma exchange; PED = periodic epileptiform discharges in EEG; RTX = rituximab; SE = status epilepticus; WBC = white blood cells. Antibody titers were defined as the highest dilution for which the reactivity with HEK cells expressing α1β3γ2 was no longer detectable.

patients treated with immunotherapy (and tumor removal when appropriate) had partial (n = 13, 72%) or complete (n = 5, 28%) recovery, and the other 3 (14%) patients died of sepsis, which in 2 was associated with status epilepticus; none of the patients who died had a tumor. One of the 2 patients who did not receive immunotherapy showed partial improvement (case 13), and the other was lost to follow-up (unknown outcome). At the last follow-up, none of the 26 patients has had a relapse. One patient (case 17) developed anti-GABA<sub>A</sub>R encephalitis 1 year after a first episode of seizures successfully treated with antiepileptic drugs. However, it is unclear whether the first episode was related to anti-GABA<sub>A</sub>R encephalitis given that no CSF, MRI, or antibody studies were obtained.

Compared to adults (table 2), children were more likely to develop generalized seizures (11/11, 100% vs 7/15, 47%, *p* = 0.007), movement disorders (7/11, 64% vs 2/15, 13%, *p* = 0.01), and CSF abnormalities (10/11, 91% vs 5/15, 33%, *p* = 0.005), and less likely to have a tumor (1/10, 10% vs 9/15, 60%, *p* = 0.01). Despite these findings, the outcome was not significantly different between the age groups (*p* = 0.06).

Compared to patients without tumor (table e-1), those with tumor were older (median 56.5 vs 16 years in patients without tumor, *p* = 0.006) and less frequently had generalized seizures (4/10, 40% vs 13/15, 87%, *p* = 0.02); the outcome, however, was similar (*p* = 0.14).

Detection of antibodies against the γ2 subunit, which in all cases occurred in association with antibodies against the α1 or β3 subunits, did not segregate with symptoms or paraclinical findings different from those in patients without γ2 subunit antibodies (data not shown).

**DISCUSSION** We report 17 new patients with anti-GABA<sub>A</sub>R encephalitis and review 9 previously reported cases providing the main clinical and radiologic clues that assist in the differential diagnosis of this disorder in children and adults, tumor and viral associations, and the main subunit targets of the antibodies, the α1 and β3 subunits of the GABA<sub>A</sub>R.

Our current findings confirm that seizures are the most frequent clinical manifestation of this disorder. Combined with data from our previous study, up to 88% of the patients had seizures, usually at symptom presentation, and frequently accompanied by status epilepticus that often required pharmacologically induced coma. Status epilepticus (along with sepsis) may have contributed to the death of 2 patients. In all patients, the seizures were accompanied by at least one of the following core symptoms: cognitive impairment, decreased level of consciousness, altered behavior, or movement disorders. Interestingly, children were more

**Table 2** Clinical features in children and adults with anti-GABA<sub>A</sub> receptor (GABA<sub>A</sub>R) encephalitis (26 patients)

	Total (26)	Children (11)	Adults (15)	p Value
<b>Demographics</b>				
Median age (range), y	40.5	13 (2.5 mo–16 y)	59 (28–88)	
Female	13/26	6/11 (55%)	7/15 (47%)	1
<b>Clinical association</b>				
Tumor	10/25	1/10	9/15	0.01 <sup>a</sup>
Other autoimmune diseases	5/26	0/11	5/15	0.05
<b>Clinical manifestations</b>				
Prodrome	9/25	4/10	5/15	1
Generalized seizures	18/26	11/11	7/15	0.007 <sup>a</sup>
Focal seizures	21/26	8/11	13/15	0.61
Status epilepticus/seizures (any type)	11/23	6/11	5/12	0.68
Decreased level of consciousness	11/26	4/11	7/15	0.7
Behavioral changes	12/26	5/11	7/15	1
Cognitive decline	16/24	6/9	10/15	1
Movement disorders	9/26	7/11	2/15	0.01 <sup>a</sup>
Dysautonomia	4/25	3/10	1/15	0.26
<b>Clinical severity</b>				
mRS ≥4 at the peak of disease	15/22	7/10	8/12	0.24
Admission to ICU	12/26	7/11	5/15	0.23
<b>Complementary studies</b>				
MRI multifocal abnormalities	20/26	8/11	12/15	1
EEG epileptiform discharges	16/21	8/10	8/11	1
EEG focal/diffuse slowing	12/21	7/10	5/11	0.38
CSF abnormal (cell count, proteins, or OCB)	15/26	10/11	5/15	0.005 <sup>a</sup>
Additional antineuronal antibodies	7/26	4/11	3/15	0.4
<b>Immunotherapy</b>				
First-line alone (steroids, PE, IVIg)	13/23	4/10	9/13	
First- and second-line (AZA, CTX, CyA, RTX)	8/23	5/10	3/13	
No immunotherapy	2/23	1/10	1/13	
<b>Outcome</b>				
Partial recovery	14/22	8/10	6/12	0.06
Complete recovery	5/22	1/10	4/12	
Death	3/22	1/10	2/12	

Abbreviations: AZA = azathioprine; CTX = cyclophosphamide; CyA = cyclosporine; ICU = intensive care unit; IVIg = IV immunoglobulins; mRS = modified Rankin Scale; OCB = oligoclonal bands; PE = plasma exchange; RTX = rituximab.

<sup>a</sup>Significant.


likely to have generalized seizures and movement disorders and less likely to have an underlying tumor than adults. These age-related symptoms may result from the combination of specific antibody effects on synaptic circuits (e.g., antibody-mediated decrease of receptors) and increased vulnerability of some areas of the

developing brain (hippocampus, basal ganglia) to inflammatory disorders. For example, other inflammation-related epileptic conditions (e.g., febrile infection-related epilepsy syndromes<sup>20</sup>) and movement disorders (e.g., postinfectious Sydenham chorea<sup>21</sup>) occur almost exclusively in children. In addition, in children, GABA<sub>A</sub>R antibodies may develop as postviral encephalitis and coexist with NMDAR antibodies, in which case the resulting symptoms (seizures, dyskinesias, choreoathetosis) are likely a manifestation of the combined presence of NMDAR antibody-mediated mechanisms.

Considering the clinical similarities among many forms of autoimmune encephalitis, an important finding of our study is the association of anti-GABA<sub>A</sub>R encephalitis with multifocal unilateral or bilateral cortical-subcortical T2/FLAIR MRI abnormalities. These T2/FLAIR abnormalities can manifest asynchronously during the course of the disease (some appear while others disappear), sometimes with limited correlation with the patient's symptoms, and rarely enhance with contrast. These MRI findings are important not only because they are frequent (77% of the patients) but also because they rarely occur in other autoimmune encephalitis, providing a valuable clue to the clinical recognition of GABA<sub>A</sub>R autoimmunity.

The experience gained from this and our previous study suggests that 40% of patients with anti-GABA<sub>A</sub>R encephalitis have tumors, mostly thymomas, and less commonly, other neoplasms (e.g., Hodgkin lymphoma, multiple myeloma) that may cause alterations of the immunologic system, perhaps leading to autoimmunity. Patients with a tumor were older (only 1 of 11 pediatric patients had a tumor; Hodgkin lymphoma in a 16-year-old patient) and less likely to have seizures than those without tumor, probably due to the general predisposition of children with inflammatory brain disorders to have seizures. Four adult patients had thymoma: 1 of them, previously reported,<sup>19</sup> had a history of several tumor relapses without development of encephalitis until the last relapse, which also associated with LGI1 antibodies. Interestingly, the thymoma of this patient expressed both LGI1 and GABA<sub>A</sub>R proteins, and the clinical picture appeared to be driven by the GABA<sub>A</sub>R immune response showing widespread multifocal (not hippocampal limited) T2/FLAIR abnormalities, which are highly unusual in anti-LGI1 encephalitis. This clinical case resembled 2 reported patients with anti-GABA<sub>A</sub>R encephalitis in association with invasive thymoma, coexisting antibodies (LGI1 or Caspr2), myasthenia gravis (in one), and multifocal T2/FLAIR MRI abnormalities.<sup>9</sup> We did not find another predominant tumor type among our patients with malignancies, as reported in previous studies.<sup>9,10</sup> It is unclear whether the history of HIV,

**Figure 2** MRI findings in 2 patients with anti-GABA<sub>A</sub> receptor (GABA<sub>A</sub>R) encephalitis



(A, B) MRI from patient 7, obtained on day 30 after symptom onset, shows extensive, confluent fluid-attenuated inversion recovery (FLAIR) abnormalities involving the left occipital lobe and the frontal and temporal regions, bilaterally, with moderate diffusion restriction (not shown). (C) MRI from patient 14, obtained on day 45 after symptom onset, shows extensive multiple cortical-subcortical FLAIR abnormalities involving bilateral frontal, temporal, and parietal-occipital lobes, without diffusion restriction, but mild gyriform leptomeningeal enhancement in the right temporal pole (not shown). Biopsy was performed in the right frontal region. (D) Follow-up MRI obtained 2.5 months later (4 months after symptom onset) shows substantial improvement and resolution of most abnormalities.

vaccination against yellow fever, or a peripheral stem cell transplant for multiple myeloma in 3 of our patients played a role in triggering the GABA<sub>A</sub>R immune response. However, it is interesting to note that post-transplant immunosuppressed patients can develop autoimmune encephalitis, as has been shown in patients with anti-NMDAR and anti-LGI1 encephalitis.<sup>22,23</sup>

The development of anti-GABA<sub>A</sub>R encephalitis as postviral encephalitis (HSV1 and HHV6) expands the number of receptors that can be involved as targets of postviral brain autoimmunity. This and previous findings<sup>24</sup> support the concept of autoimmunity triggered by extensive antigen release by infected neurons undergoing degeneration. A mechanism of viral mimicry is less likely because the 2 patients with this complication developed de novo synthesis of antibodies against 2 different targets (GABA<sub>A</sub>R and NMDAR) during the weeks following the viral encephalitis.

All patients' serum or CSF antibodies recognized the  $\alpha 1$  or  $\beta 3$  subunits of the GABA<sub>A</sub>R, with 31% of

the cases showing coexisting antibodies against the  $\gamma 2$  subunit. None of the patients had isolated antibodies against the  $\gamma 2$  subunit, and the presence of these antibodies along with antibodies to  $\alpha 1$  or  $\beta 3$  subunits did not reveal a specific subphenotype (data not shown), suggesting that CBA expressing  $\alpha 1\beta 3$  or  $\alpha 1\beta 3\gamma 2$  can be used for comprehensive antibody testing. In a previous study in which the clinical and paraclinical information (CSF, MRI, or EEG) were limited or not available for many patients, antibodies directed only against the  $\gamma 2$  subunit were identified in 5 cases.<sup>10</sup> Each of these patients had a different syndrome or suspected etiology (celiac disease, psychological disorder, mild cognitive impairment, pathologically confirmed Huntington disease, focal epilepsy) and only 1 received immunotherapy, suggesting a low index of conviction among the treating physicians for an autoimmune cause. In contrast, our current clinical findings associated with brain tissue reacting antibodies and  $\alpha 1\beta 3$  subunit specificity (irrespective of  $\gamma 2$  subunit antibodies) show a more homogeneous clinical and radiologic syndrome, and 21 of 23 patients received immunotherapy.

It is premature to indicate whether serum or CSF should preferentially be tested. We have identified GABA<sub>A</sub>R antibodies in serum, but not CSF, of patients with other disorders such as stiff-person syndrome or opsoclonus-myoclonus.<sup>8</sup> Interestingly, the samples of those patients do not react with brain tissue or cultured neurons, suggesting other epitope targets of unclear clinical relevance. This finding and the possible coexistence of CSF or serum antibodies against other synaptic or cell surface proteins<sup>8-10</sup> suggests caution in selecting only serum or CSF for antibody testing, and for these reasons we prefer determining antibodies in both samples. A comprehensive approach to antibody testing using CBA with both serum and CSF or if only serum is available confirming the results with brain tissue immunohistochemistry has been recommended for most antibodies against cell surface or synaptic proteins.<sup>11</sup> In our experience with this and other autoantibodies, the parallel demonstration of antibody reactivity using brain tissue and CBA has more clinical value than CBA alone (irrespective of the titers of this assay), as shown here in some cases.

Despite the limitations of being a retrospective study and that the disease is infrequent, the findings of this study are important in helping to recognize this potentially lethal disorder. Current experience suggests that anti-GABA<sub>A</sub>R encephalitis should be suspected in patients with encephalitis predominantly manifesting with seizures and multifocal cortical-subcortical T2/FLAIR MRI abnormalities that usually involve the temporal lobes (95% of cases). The disorder can affect very young children (the youngest

in this study was 2.5 months) and adults. In younger patients, the disorder may be confused with anti-NMDAR encephalitis due to the common presence of dyskinesias, although it is important to keep in mind that both disorders may overlap in the context of postviral autoimmune encephalitis. Compared with other autoimmune encephalitis, anti-GABA<sub>A</sub>R encephalitis seems to be less responsive to treatment than NMDAR encephalitis. Although 86% of the patients showed responses to treatment (first- and second-line therapies and tumor treatment if needed), only 28% had full recovery (and only one of them was a child), and the other 14% died, emphasizing the need for prompt recognition and treatment of the disorder. Future studies should focus on clarifying the frequency of GABA<sub>A</sub>R antibodies in patients with postviral autoimmune encephalitis, the preferential occurrence of these antibodies in serum or CSF, and whether prompt treatment improves the degree of neurologic recovery.

### AUTHOR CONTRIBUTIONS

Design/conceptualization of the study, analysis and interpretation of the data: M.S., M.P.P., and J.D. Data collection: M.S., M.P.P., M.M.S., T.A., C.F.J., M.I.B.A., M.R.J.B., L.B., M.G., A.F., R.L.C.O., M.R.R., F.G., J.D. Statistical analysis: M.S., T.A., J.D. Figure/video development: M.S., M.P.P., M.M.S., L.B., J.D. Drafting of the manuscript: M.S., M.R.R., F.G., and J.D.

### ACKNOWLEDGMENT

The authors thank the physicians who provided clinical information, the patients and families for their contribution to research, and E. Aguilar and J. Planagumà for technical support.

### STUDY FUNDING

This study was supported in part by Instituto Carlos III/FEDER (CM14/00081, T.A.; FIS PI15/00377, F.G.; FIS PI14/00203, J.D.), CIBERER (CB15/00010, J.D.), NIH RO1NS077851 (J.D.), Agaur SGR93 (J.D.), Fédération pour la Recherche sur le Cerveau, FCR-2013-01 (J.D.), Fundación Mutua Madrileña (T.A.), Fondation Pierre Mercier pour la Science and Société Académique Vaudoise (Lausanne, Switzerland) (M.S.), Dodot Procter & Gamble (DN040579, T.A.), and Fundació CELLEX (J.D.).

### DISCLOSURE

M. Spatola, M. Petit-Pedrol, M.M. Simabukuro, T. Armangue, F.J. Castro, M.I. Barcelo Artigues, M.R. Julià Benique, L. Benson, M. Gorman, A. Felipe, and R.L. Caparó Oblitas report no disclosures relevant to the manuscript. M.R. Rosenfeld receives royalties from Athena Diagnostics for the use of Ma2 as an autoantibody test and from Euroimmun for the use of NMDA receptor as an autoantibody test. F. Graus received a licensing fee from Euroimmun for the use of IgLON5 as an autoantibody test. J. Dalmau receives royalties from Athena Diagnostics for the use of Ma2 as an autoantibody test and from Euroimmun for the use of NMDA, GABA<sub>B</sub> receptor, GABA<sub>A</sub> receptor, DPPX, and IgLON5 as autoantibody tests; he has received an unrestricted research grant from Euroimmun. Go to [Neurology.org](http://Neurology.org) for full disclosures.

Received June 24, 2016. Accepted in final form October 18, 2016.

### REFERENCES

- Baulac S, Huberfeld G, Gourfinkel-An I, et al. First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene. *Nat Genet* 2001;28:46–48.
- Wallace RH, Marini C, Petrou S, et al. Mutant GABAA receptor  $\gamma$ 2-subunit in childhood absence epilepsy and febrile seizures. *Nat Genet* 2001;28:49–52.
- Maljevic S, Krampfl K, Cobilanschi J, et al. A mutation in the GABA(A) receptor alpha(1)-subunit is associated with absence epilepsy. *Ann Neurol* 2006;59:983–987.
- Lachance-Touchette P, Martin C, Poulin C, Gravel M, Carmant L, Cossette P. Screening of GABRB3 in French-Canadian families with idiopathic generalized epilepsy. *Epilepsia* 2010;51:1894–1897.
- González MI, Grabenstatter HL, Cea-Del Rio CA, et al. Seizure-related regulation of GABAA receptors in spontaneously epileptic rats. *Neurobiol Dis* 2015;77:246–256.
- Greenfield LJ. Molecular mechanisms of antiseizure drug activity at GABAA receptors. *Seizure* 2013;22:589–600.
- Sun Y, Wu Z, Kong S, et al. Regulation of epileptiform activity by two distinct subtypes of extrasynaptic GABAA receptors. *Mol Brain* 2013;6:21.
- Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. *Lancet Neurol* 2014;13:276–286.
- Ohkawa T, Satake S, Yokoi N, et al. Identification and characterization of GABA(A) receptor autoantibodies in autoimmune encephalitis. *J Neurosci* 2014;34:8151–8163.
- Pettingill P, Kramer HB, Coebergh JA, et al. Antibodies to GABAA receptor  $\alpha$ 1 and  $\gamma$ 2 subunits: clinical and serologic characterization. *Neurology* 2015;84:1233–1241.
- Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. *Lancet Neurol* 2016;15:391–404.
- Sulter G, Steen C. Use of the Barthel Index and modified Rankin Scale in acute stroke trials. *Stroke* 1999;30:1538–1541.
- Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. *Ann Neurol* 2009;65:424–434.
- Gresa-Arribas N, Planagumà J, Petit-Pedrol M, et al. Human neurexin-3 $\alpha$  antibodies associate with encephalitis and alter synapse development. *Neurology* 2016;86:2235–2242.
- Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. *Lancet Neurol* 2008;7:1091–1098.
- Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. *Lancet Neurol* 2010;9:776–785.
- Lancaster E, Huijbers MGM, Bar V, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. *Ann Neurol* 2011;69:303–311.
- Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA (B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. *Lancet Neurol* 2010;9:67–76.
- Simabukuro MM, Petit-Pedrol M, Castro LH, et al. GABAA receptor and LGI1 antibody encephalitis in a patient with thymoma. *Neurol Neuroimmunol Neuroinflammation* 2015;2:e73.
- Kramer U, Chi C-S, Lin K-L, et al. Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. *Epilepsia* 2011;52:1956–1965.

21. Williams KA, Swedo SE. Post-infectious autoimmune disorders: Sydenham's chorea, PANDAS and beyond. *Brain Res* 2015;1617:144–154.
22. Rathore GS, Leung KS, Muscal E. Autoimmune encephalitis following bone marrow transplantation. *Pediatr Neurol* 2015;53:253–256.
23. Zhao CZ, Erickson J, Dalmau J. Clinical reasoning: agitation and psychosis in a patient after renal transplantation. *Neurology* 2012;79:e41–e44.
24. Armangue T, Leypoldt F, Málaga I, et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. *Ann Neurol* 2014;75:317–323.



## Neurology® Online CME Program

Earn CME while reading *Neurology*. This program is available only to online *Neurology* subscribers. Simply read the articles marked CME, go to [Neurology.org](http://Neurology.org), and click on CME. This will provide all of the information necessary to get started. The American Academy of Neurology (AAN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. *Neurology* is planned and produced in accordance with the ACCME Essentials. For more information, contact AAN Member Services at 800-879-1960.

## Registration Now Open for 2017 AAN Annual Meeting in Boston

Discover the Annual Meeting everyone's talking about. We changed the entire format and feel of the AAN Annual Meeting for 2016—and people took notice! We're doing it again in 2017, and adding even more changes to the docket. Register today to experience the value, choice, customization, and innovation that only an AAN Annual Meeting can offer. We look forward to seeing you April 22-28 in Boston. Register today at [AAN.com/view/AM17](http://AAN.com/view/AM17).

## Discover Altmetrics

See real-time downloads and online activity for articles!



- Picked up by 8 news outlets
- Tweeted by 18
- Mentioned in 1 Google+ posts
- 12 readers on Mendeley

[See more details](#)

Authors and readers alike can view real-time data on articles including downloads and online activity across multiple sources. Click on the “Article Metrics” link in the right column of an article for details. To learn more about article metrics visit [http://www.neurology.org/site/misc/article\\_usage.xhtml](http://www.neurology.org/site/misc/article_usage.xhtml).